Mavelertinib - Pfizer

Drug Profile

Mavelertinib - Pfizer

Alternative Names: PF-06747775; PF-7775; PF6747775; PFE-X775

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Purines; Pyrazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 31 Jul 2018 Discontinued - Phase-I/II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan, Australia, South Korea, USA (PO)
  • 31 Jul 2018 Discontinued - Phase-I/II for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Australia, Japan, South Korea, USA (PO)
  • 30 Jan 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top